Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy

New England Journal of Medicine

Volumn 340, Issue 17, 1999, Pages 1301-1306

  Furrer, Hansjakob ^a   Egger, Matthias ^b   Opravil, Milos ^c   Bernasconi, Enos ^d   Hirschel, Bernard ^e   Battegay, Manuel ^f   Telenti, Amalio ^g   Vernazza, Pietro L ^h   Rickenbach, Martin ⁱ   Flepp, Markus ^c   Malinverni, Raffaele ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^f KANTONSSPITAL BASEL   (Switzerland)

^g LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^h Kantonsspital St Gallen   (Switzerland)

ⁱ Data Center   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; DAPSONE; PENTAMIDINE; PYRIMETHAMINE;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; DISEASE ASSOCIATION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RATE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTI-INFECTIVE AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PNEUMONIA, PNEUMOCYSTIS; PRIMARY PREVENTION; TOXOPLASMOSIS, CEREBRAL;

EID: 0033614421     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199904293401701     Document Type: Article

References (33)

1. Update: acquired immunodeficiency syndrome - United States. MMWR Morb Mortal Wkly Rep 1986;35:757-60, 765-6.
2. Hoover DR, Saah AJ, Bacellar H, et al. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. N Engl J Med 1993;329:1922-6.
3. Harris JE. Improved short-term survival of AIDS patients initially diagnosed with Pneumocystis carinii pneumonia, 1984 through 1987. JAMA 1990;263:397-401.
4. Chaisson RE, Gallant JE, Keruly JC, Moore RD. Impact of opportunistic disease on survival in patients with HIV infection. AIDS 1998;12:29-33.
5. Phair J, Muñoz A, Detels R, et al. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. N Engl J Med 1990;322:161-5.
6. Hirschel B, Lazzarin A, Chopard P, et al. A controlled study of inhaled pentamidine for primary prevention of Pneumocystis carinii pneumonia. N Engl J Med 1991;324:1079-83.
7. Schneider MME, Hoepelman AIM, Eeftinck Schattenkerk JKM, et al. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole asth h primary prophylaxis against Pneumocystis carinii pneumonia in patients wiuman immunodeficiency virus infection. N Engl J Med 1992;327:1836-41.
8. Bozzette SA, Finkelstein DM, Spector SA, et al. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995;332:693-9.
9. Bucher HC, Griffith L, Guyatt GH, Opravil M. Meta-analysis of prophylactic treatments against Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1997;15:104-14.
10. Opravil M, Hirschel B, Lazzarin A, et al. Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients. Clin Infect Dis 1995; 20:531-41.
11. Carr A, Tindall B, Brew BJ, et al. Low-dose trimethoprim-sulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS. Ann Intern Med 1992;17:106-11.
12. Recommendations for prophylaxis against Pneumocystis carinii pneumonia for adults and adolescents infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1992;41(RR-4):1-11.
13. Masur H. Prevention and treatment of pneumocystis pneumonia. N Engl J Med 1992;327:1853-60. [Erratum, N Engl J Med 1993;328: 1136.]
14. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-9.
15. Egger M, Hirschel B, Francioli P, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. BMJ 1997;315:1194-9.
16. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
17. Pakker NG, Notermans DW, de Boer RJ, et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med 1998;4:208-14.
18. Connors M, Kovacs JA, Krevat S, et al. HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Med 1997;3:533-40.
19. Li TS, Tubiana R, Katlama C, Calvez V, Ait Mohand H, Autran B. Long-lasting recovery in CD4 T-cell function and viral load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998;351:1682-6.
20. + repertoire during antiviral therapy. Nat Med 1998;4:215-21.
21. USPHS/IDSA Prevention of Opportunistic Infections Working Group. Preface to the 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. Clin Infect Dis 1997;25:Suppl 3:S299-S312.
22. Ledergerber B, von Overbeck J, Egger M, Lüthy R. The Swiss HIV Cohort Study: rationale, organization and selected baseline characteristics. Soz Praventivmed 1994;39:387-94.
23. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992;41(RR-17):1-19.
24. Schockmel GA, Yerly S, Perrin L. Detection of low HIV-1 RNA levels in plasma. J Acquit Immune Defic Syndr Hum Retrovirol 1997;14:179-83.
25. Taylor JM, Fahey JL, Detels R, Giorgi JV. CD4 percentage, CD4 number, and CD4:CD8 ratio in HIV infection: which to choose and how to use. J Acquir Immune Defic Syndr 1989;2:114-24.
26. Kidd PG, Cheng SC, Paxton H, Landay A, Gelman R. Prediction of CD4 count from CD4 percentage: experience from three laboratories. AIDS 1993;7:933-40.
27. Torres RA, Barr M, Thorn M, et al. Randomized trial of dapsone and aerosolized pentamidine for the prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. Am J Med 1993;95:573-83.
28. Currier JS. OI prophylaxis in antiretroviral responders: stay the course or bite the bullet? AIDS Clin Care 1998;10:73-5, 79-80.
29. Schneider MME, Borleffs JCC, Stolk RP, Jaspers CA, Hoepelman AIM. Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy. Lancet 1999;353:201-3.
30. Tural C, Romeu J, Sirera G, et al. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients. J Infect Dis 1998;177:1080-3.
31. Macdonald JC, Torriani FJ, Morse LS, Karavellas MP, Reed JB, Freeman WR. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy. J Infect Dis 1998;177:1182-7.
32. Michelet C, Arvieux C, François C, et al. Opportunisitc infections occurring during highly active antiretroviral treatment. AIDS 1998;12:1815-22.
33. Gebhardt M, Rickenbach M, Egger M, Swiss HIV Cohort Study. Impact of antiretroviral combination therapies on AIDS surveillance reports in Switzerland. AIDS 1998;12:1195-201.